Literature DB >> 15201234

B type natriuretic peptide testing: where are we now?

M R Cowie.   

Abstract

It is possible that plasma BNP measurement might be to heart failure what glycated haemoglobin measurement is to diabetes mellitus. Indeed, within 12-24 months, BNP testing might become a routine addition to the monitoring of patients with heart failure. In the meantime its main role is in helping to rule out heart failure in patients with new symptoms

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15201234      PMCID： PMC1768306          DOI： 10.1136/hrt.2003.014787

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  16 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.

Authors:  Torbjørn Omland; Anita Persson; Leong Ng; Russel O'Brien; Thomas Karlsson; Johan Herlitz; Marianne Hartford; Kenneth Caidahl
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

3.  Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study.

Authors:  H Smith; R M Pickering; A Struthers; I Simpson; D Mant
Journal:  BMJ       Date:  2000-04-01

Review 4.  BNP and congestive heart failure.

Authors:  Martin R Cowie; Gustavo F Mendez
Journal:  Prog Cardiovasc Dis       Date:  2002 Jan-Feb       Impact factor: 8.194

5.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

Authors:  V Cheng; R Kazanagra; A Garcia; L Lenert; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

6.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.

Authors:  Q Dao; P Krishnaswamy; R Kazanegra; A Harrison; R Amirnovin; L Lenert; P Clopton; J Alberto; P Hlavin; A S Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  Biochemical detection of left-ventricular systolic dysfunction.

Authors:  T A McDonagh; S D Robb; D R Murdoch; J J Morton; I Ford; C E Morrison; H Tunstall-Pedoe; J J McMurray; H J Dargie
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

8.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

9.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.

Authors:  F D R Hobbs; R C Davis; A K Roalfe; R Hare; M K Davies; J E Kenkre
Journal:  BMJ       Date:  2002-06-22

10.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

Authors:  Ramachandran S Vasan; Emelia J Benjamin; Martin G Larson; Eric P Leip; Thomas J Wang; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2002-09-11       Impact factor: 56.272
View more
  1 in total

1.  Comparison of BNP and NT-proBNP assays in the approach to the emergency diagnosis of acute dyspnea.

Authors:  M P Sanz; L Borque; A Rus; B Vicente; Y Ramírez; L Lasa
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.